Title : Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.

Pub. Date : 2018 Aug 15

PMID : 29526950






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A 63-year-old woman with pulmonary adenocarcinoma (stage IIIB) that was positive for an epidermal growth factor receptor (EGFR) mutation and an anaplastic lymphoma kinase (ALK) rearrangement was treated with erlotinib as the first-line treatment, resulting in a stable disease. Erlotinib Hydrochloride ALK receptor tyrosine kinase Homo sapiens
2 A 63-year-old woman with pulmonary adenocarcinoma (stage IIIB) that was positive for an epidermal growth factor receptor (EGFR) mutation and an anaplastic lymphoma kinase (ALK) rearrangement was treated with erlotinib as the first-line treatment, resulting in a stable disease. Erlotinib Hydrochloride ALK receptor tyrosine kinase Homo sapiens